Chris Chai and Peter Van Vlasselaer, Ph.D. Join Investing Team with Strong Track Records in Biotechnology Industry SAN FRANCISCO & LONDON, February 11, 2021-- SR One, a trans-Atlantic venture capital firm investing in life sciences companies, announced today that Chris Chai and Peter Van Vlasselaer, Ph.D. have joined the firm as Venture Partners. Both individuals have strong track records in the formation and evolution of early-stage biotechnology companies, with an emphasis on drug development, fundraising, and operations. “Chris and Peter bring an extraordinary depth of financial and drug-hunting expertise to our team.